BioSpace News Archive

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday March 4, 2021.

WaveMark™ Supply Management & Workflow Solutions to help health systems improve outcomes through clinically integrated supply chain model

Agilent Technologies Inc. (NYSE: A) today announced the launch of the Agilent Dako SARS-CoV-2 IgG Enzyme-Linked Immunosorbent Assay (ELISA) kit intended for the qualitative detection of immunoglobulin G (IgG) antibodies to SARS-CoV-2 in human serum or plasma.

Restorative Therapies, Inc – the leading provider of innovative, integrated therapeutic medical devices that are the standard of care in rehabilitation therapy for many neurological conditions – announced today the launch of Xcite2.

Centene Corporation (NYSE: CNC) (“Centene” or the “Company”) announced the results of its previously announced tender offer (the “Tender Offer”) to purchase for cash any and all of its outstanding $2,200,000,000 aggregate principal amount of 4.75% Senior Notes due 2025 (the “2025 Notes”) from each registered holder of the 2025 Notes (the “Holders”),

Varian (NYSE: VAR) announced it has joined the Cancer Drug Development Forum (CDDF) as an industry partner.

Particle therapy or radiation therapy involves use of X-rays and high energy rays that destroy the cancerous cells in the tumor or target area.

Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced positive safety and efficacy results from a planned interim analysis of PSOARING 3, its long-term, open-label safety study that, along with previously reported PSOARING 1 and PSOARING 2 pivotal efficacy trials,

Next Generation Sequencing or NGS is an outstanding technology that arranges massive DNA strands through enormous parallelization.

Digital therapeutics (DTx) is tasked with the delivery of therapeutic interventions that are based on evidence.